AbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow ABBV
AbbVie Inc. (ABBV) Debt to equity
AbbVie Inc.'s debt to equity at the end of the quarter to 30 June 2026 was −12.0×, up 8.9× from fiscal 2025 (−20.9×). Over the past ten years it has ranged from −20.9× (fiscal 2025) to 20.0× (fiscal 2024) — the current reading is the lowest in ten years. That is below the Drug Manufacturers General industry median of 0.6× and below the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | −20.9× | — |
| FY2024 | 20.0× | 249.45% |
| FY2023 | 5.7× | 56.06% |
| FY2022 | 3.7× | (26.33%) |
| FY2021 | 5.0× | (24.39%) |
| FY2020 | 6.6× | — |
| FY2019 | −8.2× | — |
| FY2018 | −4.8× | — |
| FY2017 | 7.3× | (7.75%) |
| FY2016 | 7.9× | (1.01%) |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | −12.0× | — |
| Mar 2026 | −11.0× | — |
| Dec 2025 | −20.9× | — |
| Sep 2025 | −26.4× | — |
| 42 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| ABBV AbbVie Inc. | −12.0× |
| JNJ Johnson & Johnson compare | 0.4× |
| AZN AstraZeneca PLC compare | 0.6× |
| PFE Pfizer Inc. compare | 0.7× |
| NVS Novartis AG compare | 1.1× |
| MRK Merck & Co., Inc. compare | 1.2× |
| LLY Eli Lilly and Company compare | 1.6× |
| GILD Gilead Sciences, Inc. compare | 2.2× |
| AMGN Amgen Inc. compare | 4.9× |
| Drug Manufacturers General industry median | 0.6× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on ABBV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement